Bris­tol My­ers scores an­oth­er Op­di­vo ap­proval, as Mer­ck con­verts AA to full ap­proval for Keytru­da in MCC

Bris­tol My­ers Squibb on Fri­day nabbed an­oth­er ap­proval for its block­buster can­cer treat­ment Op­di­vo.

The drug was ap­proved to treat pa­tients ages 12 and old­er with com­plete­ly re­sect­ed stage IIB or IIC melanoma based on pos­i­tive re­sults from the Phase III Check­Mate -76K tri­al, which showed a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in re­cur­rence-free sur­vival com­pared to a place­bo. Op­di­vo’s new ap­proval comes as Mer­ck’s Keytru­da al­so gar­nered a win from the FDA — a full ap­proval for the treat­ment of Merkel cell car­ci­no­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER